A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

Trial Details

NCT ID
NCT06997029
Phase
PHASE1
Sponsor
Bristol-Myers Squibb
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • BMS-986500
  • Palbociclib
  • Fulvestrant
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Fullerton, California, United States|33.87029,-117.92534
  • Greenbrae, California, United States|37.94854,-122.5247
  • La Jolla, California, United States|32.84727,-117.2742
  • Newport Beach, California, United States|33.61891,-117.92895

Key Eligibility Criteria

  • Participants must be ≥ 18 years of age.
  • Participants must have histologically confirmed diagnosis of a locally advanced, unresectable, or metastatic solid tumor malignancy.
  • Participants must have a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  • Participants must have a stable Eastern Cooperative Oncology Group Performance Status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →